Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06647459 · ClinicalTrials.gov registry record
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
A clinical trial of Atrial Fibrillation and Ventricular Tachycardia, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06647459 is a study of Atrial Fibrillation and Ventricular Tachycardia that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 200 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06647459, a study of Atrial Fibrillation and Ventricular Tachycardia, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST EP Study
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2027-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06647459
The ClinicalTrials.gov registry entry for NCT06647459 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which EP Study is the first listed.
NCT06647459 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06647459 about?
NCT06647459 is a clinical study titled "Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation". To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in pat...
What is the current status of trial NCT06647459?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-12-13. Estimated completion is 2027-01-01.
What conditions does trial NCT06647459 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Ventricular Tachycardia.
What interventions are being tested in trial NCT06647459?
The interventions under investigation include: EP Study (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06647459?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06647459 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.